GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Products » Solvonis Therapeutics PLC (LSE:SVNS) » Definitions » Capex-to-Operating-Income

Solvonis Therapeutics (LSE:SVNS) Capex-to-Operating-Income : 0.00 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Solvonis Therapeutics Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Solvonis Therapeutics's Capital Expenditure for the six months ended in Jun. 2024 was £-0.00 Mil. Its Operating Income for the six months ended in Jun. 2024 was £-0.54 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Solvonis Therapeutics Capex-to-Operating-Income Historical Data

The historical data trend for Solvonis Therapeutics's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solvonis Therapeutics Capex-to-Operating-Income Chart

Solvonis Therapeutics Annual Data
Trend May18 May19 May20 May21 Dec22 Dec23
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Solvonis Therapeutics Semi-Annual Data
May18 May19 May20 May21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Solvonis Therapeutics's Capex-to-Operating-Income

For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Solvonis Therapeutics's Capex-to-Operating-Income Distribution in the Industrial Products Industry

For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Solvonis Therapeutics's Capex-to-Operating-Income falls into.



Solvonis Therapeutics Capex-to-Operating-Income Calculation

Solvonis Therapeutics's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.232) / -2.21
=N/A

Solvonis Therapeutics's Capex-to-Operating-Income for the quarter that ended in Jun. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.004) / -0.544
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Solvonis Therapeutics  (LSE:SVNS) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Solvonis Therapeutics Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Solvonis Therapeutics's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Solvonis Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
Eccleston Yards, 25 Eccleston Place, London, GBR, SW1W 9NF
Graft Polymer (UK) PLC focuses on the development of polymer modification and drug delivery systems. It has licensed its Drug Delivery System platform IP to MGC Pharmaceuticals in relation to MGC Pharma's CimetrA product. The group's products address customer needs across a wide range of end-use markets, from automotive through to medical, and are not dependent on one market segment. The Company operates in two business segments being polymer development and production in Slovenia.

Solvonis Therapeutics Headlines

No Headlines